2026

Jake Leach became DexCom’s chief executive on January 1 and is trying to write the turnaround story of this innovative medtech company. One story to tell is how CGMs should be a no-brainer for type 2 diabetes patients on GLP-1 weight loss drugs. The post DexCom’s CEO Believes Diabetics On GLP-1s Should Also Wear CGMs…

Veradermics’s drug, a pill version of the topical hair loss product minoxidil, was developed with technology intended to avoid the cardiovascular risks associated with oral dosing of this compound. The first of three pivotal clinical trials is expected to yield preliminary data in the first half of 2026. The post Baldness Biotech Veradermics Prices $256M…

Virtual women’s health provider Midi Health has reached unicorn status after raising a $100 million Series D, with investors backing its insurance-covered, direct-to-consumer model. The company is positioning itself as a long-term, virtual “hospital without walls” designed to meet women’s health needs across midlife and beyond. The post Digital Health’s Latest Unicorn: Why Investors Are…

beHuman’s $4 million seed round was led by Santé Ventures, with participation from DHVP.io. It will help expand its footprint. The post Cancer Detection Startup Secures $4M to Expand Access in Underserved Communities appeared first on MedCity News.

Billing frustration isn’t just a provider problem; it’s a patient problem too. Every delayed claim, every error, every confusing denial ultimately affects the person receiving care. Now AI can reduce that friction. The post The $25.7B Healthcare Problem AI Is Finally Solving appeared first on MedCity News.

Some specialties, like oncology, have been quicker to embrace the promise of pharmacogenomics (PGx), and their successes can serve as a roadmap as others explore the impact it can have on quality, outcomes and patient satisfaction. The post PGx Testing: Specialists Benefit From, and Build Upon Oncology’s Success appeared first on MedCity News.